Skip to main content

Market Overview

Wall Street's M&A Chatter From November 1: Dunkin Brands, Novartis, Owens & Minor-Halyard Health


The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday, November 1, 2017.

Dunkin Donuts Buyout Won't Happen this Year

The Rumor:

Shares of Dunkin Brands Group Inc (NASDAQ: DNKN) fell Wednesday, on a unconfirmed chatter that a buyout by JAB Holdings would be delayed until 2018, according to sources. On Monday, a rumor circulated that JAB had a interest in a potential deal.

Dunkin Brands closed Wednesday at $58.76, down 31 cents.

Novartis Considering Sale of its Dermatology Generics Unit

The Rumor:

Novartis AG (ADR) (NYSE: NVS) is considering selling its dermatology generics drugs business, according to sources as reported by Bloomberg. Novartis wants to divest its less profitable segments and focus on cancer, the sources said.

Novartis declined comment.

Novartis closed at $82.77, up 19 cents.

Owens & Minor to Acquire Halyard Health's Surgical, Infection Prevention Unit for $710M in Cash

The Deal:

Owens & Minor, Inc. (NYSE: OMI) announced it signed an agreement to acquire the surgical and infection prevention business of Halyard Health Inc (NYSE: HYH) for approximately $710 million in cash.

The transaction has been approved by the boards of directors of both companies and is expected to close in Q1 of 2018.

Halyard Health closed at $45.22, up $3.07. Owens & Minor closed at $20.96, down $3.61.


Related Articles (DNKN + HYH)

View Comments and Join the Discussion!

Posted-In: M&A News Rumors Pre-Market Outlook

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at